Skip to content

Author

M. Kharfan-Dabaja

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Impact of chronic obstructive pulmonary disease on survival after chimeric antigen receptor T-cell therapy in large B-cell lymphoma.

BACKGROUND Chimeric antigen receptor T-cell (CAR T-cell) therapy is the standard of care for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The impact of pre-existing chronic obstructive pulmonary disease (COPD) on outcomes of LBCL after CAR-T cell therapy are not well characterized. This study aimed at evalua...

M. Uyanik, Athanasios Tsalatsanis, I. Muhsen et al. · 0 citations
Review Oct 2026

Hyperacute Graft-Versus-Host Disease.

M. Uyanik, J. Pidala, M. Kharfan-Dabaja · 0 citations
Review Open access Sep 2026

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article.

This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, tha...

Abdulrahman Nasiri, R. El Fakih, C. Chabannon et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.